THURSDAY
June 17 11:30 - 12:30 ET
Quality Control and High-Sensitivity Cardiac Troponin Testing: More Than Just Precision Targets
  Sponsored by  thermofisher170x45
KAVSAK 150x212

 

Speaker:

Peter Kavsak, PhD
Professor
Department of Pathology and Molecular Medicine
McMaster University
Hamilton ON

Overview:

With the advent of high-sensitivity cardiac troponin testing quality control and assurance practices for monitoring test performance have changed. This seminar will review current recommendations in this area and illustrate how quality control and quality assurance practices can detect errors in testing that can impact patient care.

Learning Objectives:
  1. Describe the quality control levels and precision targets needed for high-sensitivity cardiac troponin (hs-cTn) assays
  2. Apply an approach for investigating discordant hs-cTn results after errors detected by quality control and assurance testing
  3. Appreciate the impact of analytical interferences on patient classification for myocardial injury in the hospital setting
RegisterNow 150x56 
  
WEDNESDAY
June 23  11:30-12:30 ET
SARS-CoV-2 Serology - Latest Innovations in Assay Design and Clinical Practice 
  Sponsored by diasorin150x139 
 Dr Engman 150x165

Speaker:

David M. Engman, MD, PhD
Chairman Emeritus of Pathology
Cedars Sinai Medical Center
Clinical Professor of Pathology, UCLA
Adjunct Professor Pathology, Northwestern University

 
 Dr Streva 150x200  

Speaker:

Vincent Streva, PhD
Associate Lab Director
Sherman Abrams Laboratory

 

   
Overview: Serological testing for SARS-CoV-2 has been adopted into clinical practice over the course of the COVID-19 pandemic. With the global availability of vaccines, Serology applications could evolve to benefit public health and further the understanding of the immune response.

This presentation will include a global perspective of emerging Serology clinical applications and touch upon the latest innovations in Serological assay design. Two data studies will expand on the immune response after SARS-CoV-2 natural infection and post COVID-19 vaccination.

 Learning Objectives:
  1. Current and emerging SARS-CoV-2 serology clinical applications: a Global perspective
  2. Latest innovations in SARS-CoV-2 serology assays design: trimeric spike protein as a capture antigen
  3. Immune response of individuals after natural infection with SARS-CoV-2: data study with trimeric spike and S1-RBD based IgG assays
  4. Immune status monitoring post BNT162b2 (Pfizer-BioNTech) COVID-19 mRNA vaccination: study in healthcare workers 
 RegisterNow 150x56

  
THURSDAY
July 15  11:30-12:30 ET
Plasma Volume Status in Heart Failure: Clinical Implications and Future Directions
A Point-of-Care Device for Measuring Plasma Volume in Critically Ill Patients
 
  Sponsored by NovaBiomedical 160x60 
 Girerd 150x162

Speaker:

Nicolas Girard, MD, PhD
Professor of Medicine Centre Hospitalier
Universitaire de Nancy, Centre d'investigation Clinique Pluithématique
Institut Lorrain du Coeur et des Vaisseaux

 Dennis Begos 150x162 Speaker:

Dennis Begos, MD, FACS, FACRS
Associate Medical Director
Medical and Scientific Affairs
Nova Biomedical

 Overview: Plasma Volume Status in Heart Failure: Clinical Implications and Future Directions:
Congestion is one of the main predictors of poor outcome in patients with heart failure (HF). Assessing and monitoring congestion is essential for optimizing HF therapy. Among the various available methods, serial measurements of estimated plasma volume (ePVS) using routine blood count and/or body weight (e.g., the Strauss, Duarte, Hakim formulas may be useful in HF management. This webinar will summarize the recent evidence upporting the association of ePVS with clinical congestion and outcomes and discuss future directions for monitoring ePVS in congestive heart failure (CHF) patients. 
 

A Point-of-Care Device for Measuring Plasma Volume in Critically Ill Patients:
Plasma volume is one of the top priorities in evaluating and treating many different conditions including shock, sepsis, CHF, acute or chronic kidney disease, and pulmonary disease. ePVS can be calculated only by using measured hematocrit and measured hemoglobin. Studies have shown that both ePVS and percent change values (ΔePVS) are good markers for assessing a patient’s volume status and for guiding therapy. Stat Profile Prime Plus® critical care analyzers report both ePVS and ΔePVS real-time at the bedside as part of a comprehensive blood gas/critical care test profile. 

 Objectives:
  1. Learn how ePVS is calculated and why it is a good marker for assessing a patient’s volume status and guiding therapy.
  2. Understand recent evidence supporting the association of ePVS with clinical congestion and outcome(s).
  3. Explore future directions for monitoring ePVS in congestive heart failure (CHF) patients. 
   RegisterNow 150x56